Non-invasive angina treatment close to approval:
This article was originally published in Clinica
Executive Summary
Following the completion of initial bench trials, CPC of America intends to submit a premarket approval application in the US within six months for its counter-pulsation device for treating angina. The Sarasota, Florida-based company plans to carry out a clinical study to see how well the device, called CPCA2000, relieves angina or chest pain in patients who did not respond to conventional therapy. The treatment, which uses external pressure cuffs to force blood back through blocked arteries, could be an alternative to angioplasty and surgery.